Eric Blanchard advises clients on initial public offerings, follow-on equity offerings, pre-IPO financings, investment-grade, high-yield and convertible debt offerings, liability management transactions, proxy contests and acquisitions. He counsels domestic and foreign public and private companies, with an emphasis on those in the healthcare industry, as well as investment banks. He also regularly represents public companies with securities and disclosure issues and corporate governance matters.

Download full bio 


  • SOPHiA Genetics – $234 Million IPO 

  • Xometry – $348 Million IPO 

  • GH Research – $184 Million IPO 

  • Immunocore $312.1 Million Aggregate Financing 

  • SPAC BowX Agrees to $9 Billion Merger With WeWork 

  • View all

He has been absolutely brilliant. He is relaxed, measured, on top of all the issues and a delight to deal with. – Client Testimonial, Chambers USA 2020

  • Catholic University of America, Columbus
    JD, magna cum laude, 1999

  • University of Maryland
    BA, 1996

Admissions & Credentials

New York

Rankings & Accolades

    Chambers USA: Capital Markets: Debt & Equity

    Legal 500: Key Lawyer – Capital Markets: Equity Offerings